Blue Water Vaccines, Inc.(Nasdaq: BWV) a biopharmaceutical company developing vaccines, recently announced the pricing of its initial public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. The company (Nasdaq: BWV) has grown up exponentially since the IPO share has been offered. If we look at the past trends and market analysis the share price is expected to grow even further.
The following financial analysis is the comparison between
the two companies Blue Water Vaccine (Nasdaq: BWV) and Moderna (Nasdaq: MRNA) both are
biotechnology companies focused on delivering vaccines and medicine which will
assist in preventing infectious diseases.
As per the Annual accounts, Blue Water Vaccine is spending
on the building of influenza S. pneumoniae induced AOM norovirus-rotavirus and
norovirus-malaria. Blue Water Vaccine (Nasdaq: BWV)
Both the companies are incurring high costs on the
development of new vaccines which could be potential next pandemic strain. Blue
water vaccine is typically incurring expenses on the development of new
vaccines such as the BWV-102 Stand-Alone H1 Vaccine, to address potential
pandemic zoonotic H1 strains and BWV-201 Streptococcus pneumoniae (S.
pneumoniae) Vaccine or AOM. As per the Annual accounts, Blue
Water Vaccine is spending on the building of influenza S. pneumoniae induced
AOM norovirus-rotavirus, and norovirus-malaria. Apart from the above two there
are some other Vaccine are also in the pipeline which are Universal Flu shots,
Norovirus/ Rotavirus, and Norovirus/ Malaria.
On the other hand, Moderna has famously made a vaccine for
Covid 19. There are several vaccines which are in pipeline for the treatment of
Covid-19 vaccine which will deal with the number of covid different variants
such as Beta, Delta, Beta Variant plus wild type, Beta plus Delta variant,
Omicron variant, Omicron plus wild type, and next generation (2.5 c). In
addition, there are five different types of flu vaccine for the adults. In all
Moderna has 25 different vaccines under development with different IDs.
Hence, both the companies are working under the betterment
of the future and make the world a better and healthy place to live. But the
growth potential is more on the BLUE WATER VACINNE as they are working on the
development of unique Vaccine where as Moderna is working more on Covid 19
which is already been dealt with and now clearly seen as a less threat around
the world. Most countries has already lifted the ban when it comes to covid
restrictions.
The share price for Blue Water Vaccine at Nasdaq as of now
when this article is being written is trading at $ 61.92 and the share price
for Moderna at Nasdaq is of $ 176.59 Source: Yahoo Finance.
Thesis:
From the investor's point of view both the companies are
incurring heavy operating losses, but it is understandable as there are no
substantial revenues incurring either for both companies. For Blue water
Vaccine there are no revenue reported in the company financial statements. The
same is the situation with the Moderna they have some Grant Revenues, also they
are selling their products worldwide and have some collaboration revenue.
Whereas BWV are incurring expenses in developing the product and their product
is not yet marketed. They are preparing the solution for the future challenges
world might face as per the scientist of BMV.
The Vaccine they are making (S. pneumoniae) Vaccine or AOM. The Global AOM rate is
10.85% or 709 million cases per year and which will affect the
children under 5 years
Research and Development Costs:
Both the companies are spending heavy funds on Research and
Development, and the R&D expenses are increasing on yearly basis.
|
R&D |
FY 2021 |
FY 2020 |
FY 2019 |
|
Blue
Water Vaccine |
$
1,325,030 |
$
524,908 |
$
60,174 |
|
Moderna |
$
1,991,000 |
$
1,370,339 |
$
496,309 |
The above graph shows that Moderna is spending more heavily
on Research and Development Expenses as compared to Blue Water Vaccine, but the
rise in R&D is higher side on the BWV as from 2019 – 2020 the increase is
of 772.32% and from FY 2020-2021 the increase is of 152.43% whereas If we
compare the same results with Moderna the increase in FY 2020 is of 176.11% and
in FY 2021 this increase is only of 45.29%. Therefore, clearly, the results
shows that BWV are increasing the R&D costs aggressively. To have a fast
result. This also because Moderna has now established its product in the market
and now they are making steady sales and income from it. On the other hand, the
product upon which BWV are working is yet to be introduced in the market and in
future one can expect high demand for the same.
CASH Reserves to R&D Expense
for BWV:
Here let’s see the Cash Reserves the BWV has over the years
against the R&D. The following table has been taken from the annual
accounts of the BMV.
|
FY |
2021 |
2020 |
2019 |
|
Cash
Equivalent |
$
1,928,474 |
$
4,308,821 |
$
6,050,751 |
|
R&D |
$
1,325,030 |
$
524,908 |
$
60,174 |
The percentage for R&D for FY 2019 was 0.99% where BWV
has excessive cash and not much R&D Expenses were incurring. In the FY 2020
it increases to 12.18% and in the FY 2021 it increases to 68.71% where BMV are
using their Cash in the development of new products. The main liquid funds have
been utilized in seeking licenses as well. The significant increase in the
percentage for 2021 is due to company incurring significant losses and this
will continue to incur for the foreseeable future as well. However, when the
vaccines they are making goes into the market it where BMV will be able to make
income which is like the case for Moderna.
As per the annual accounts of BMV they have completed
Initial public Offerings (IPO) on February 23, 2022, and through this they were
able to raise additional $ 17.2 million.
The BWV has made an agreement with the Oxford University
Research Agreement for which they have paid $ 554,802 to Oxford. They are also
in agreement with the St. Jude Children Hospital under they are obliged to pay
royalties and other payments when they will reach specific targets.
As BWV is expected to incur continued losses for foreseeable
future, they are expected to raise additional cash through debt financing. If
due to some reasons they are not able to raise debt, then company will look to
overcome expenses.
|
FY |
2021 |
2020 |
2019 |
|
Cash
Reserves |
$
1,928,474 |
$
4,308,821 |
$
6,050,751 |
|
Total
operating Expenses |
$
3,417,334 |
$
1,622,069 |
$
880,232 |
The Total operating expenses of the company has also
increased over the years as the increase in FY 2021 is of 110.68% and in FY
2020 it was 84.28% from previous years. These expenses mainly consists of
General and administrative expenses and Research and Development Expenses. No
significant break up of General and Admin expenses have been given but they
might consist of Office, Salary and admin expenses. As mentioned BMV management
does plan to lower these expenses if no significant cash has been raised in the
upcoming years.
The Current ratio for the FY 2021 is at 1.88 times as
compared to 66.94 and 79.97 times in the FY 2020 and FY 2019 which means
company still have enough assets to pay out its liabilities if they fall due.
The Accounts payable of the company has increased
significantly in the FY 2021 to 747.65% which is due to payments for purchasing
of different licenses and other administrative cost.
Earnings per Share:
The EPS for the Blue Water Vaccine currently is -1.01 as
compared to Moderna having an EPS of 28.29.
There are no Price Earnings Ratios available for the BWV and
the management have not announced any dividends which is again understandable
as the company is not generating any revenues.
The below chart taken from Yahoo finance shows the
performance of share price of BWV for the last three years and it shows that he
share price is increasing. Therefore, it might be a good option to invest in
this company.
Summary:
Biotech research and the company investing in the biotech
research are the future, as in the upcoming years world will continue to face
different kind of challenges. To survive them significant research work is
going on and Investors should invest and help these companies to grow.
Companies like Blue water Vaccine which are developing significant medicine. We
also have the example of Moderna which also incurred heavy losses but was able
to make Income once they established the vaccines and able to be sold it. The
same case should be except for Blue Water Vaccine.
Blue Water Vaccine: https://ir.bluewatervaccines.com/
Mordena: https://www.modernatx.com/
No comments:
Post a Comment